What does Aktis Oncology, Inc. do?
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase…
What is Aktis Oncology, Inc.'s P/E and P/B ratio?
Aktis Oncology, Inc. has a P/E ratio of -9.9 and a P/B ratio of 1.92.
What is Aktis Oncology, Inc.'s debt-to-equity ratio?
Aktis Oncology, Inc. has a debt-to-equity ratio of 0.02.
How much does Aktis Oncology, Inc. owe compared with what it owns?
Aktis Oncology, Inc. owes $0.13 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Aktis Oncology, Inc.'s Positivity rank?
Aktis Oncology, Inc. is ranked #2,813 of 6,774 companies globally and #1,020 of 4,000 in United States on PositoAI, with a Positivity Score of 21,117.
Does Aktis Oncology, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Aktis Oncology, Inc..
Where can I read the latest news about Aktis Oncology, Inc.?
Recent headlines about Aktis Oncology, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Aktis Oncology, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Aktis Oncology, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.